miRNA control of apoptotic programs: focus on ovarian cancer

被引:10
作者
Mezzanzanica, Delia [1 ]
Canevari, Silvana [1 ]
De Cecco, Loris [1 ]
Bagnoli, Marina [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Milan, Italy
关键词
apoptosis; apoptosis regulation; drug resistance; microRNA; miRNA; ovarian cancer; CELL-DEATH; CD95-MEDIATED APOPTOSIS; CYTOCHROME-C; MICRORNAS; PROTEIN; EXPRESSION; CISPLATIN; TARGET; CD95; FAMILY;
D O I
10.1586/ERM.11.1
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
miRNAs are a class of small non-coding RNAs that regulate the stability or translational efficiency of targeted mRNAs. miRNAs are involved in many cellular processes, such as differentiation, proliferation and apoptosis, which are altered in cancer through miRNA expression dysregulation. In this article we will discuss recent findings implicating miRNAs in apoptotic program regulation using ovarian carcinoma as an example. Ovarian cancer is the most lethal gynecological malignancy. Most patients are diagnosed with advanced disease that is conventionally managed with surgical resection followed by platinum-based chemotherapy. Killing of cancer cells by chemotherapeutic agents or by triggering cell-surface death receptors relies on activation of apoptotic programs executed through receptor-mediated extrinsic pathways and mitochondrial-dependent intrinsic pathways. Despite an initial good response to chemotherapy, ovarian cancer patients typically experience disease relapse within 2 years of the initial treatment developing resistance even to structurally different drugs. Thus, also in this pathology, tumor cells are able to evade apoptosis using multiple mechanisms, several of which are dependent on miRNA gene regulation.
引用
收藏
页码:277 / 286
页数:10
相关论文
共 83 条
[1]
Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells [J].
Abedini, Mohammad R. ;
Muller, Emilie J. ;
Brun, Jan ;
Bergeron, Richard ;
Gray, Douglas A. ;
Tsang, Benjamin K. .
CANCER RESEARCH, 2008, 68 (12) :4511-4517
[2]
Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro [J].
Abedini, MR ;
Qiu, Q ;
Yan, XJ ;
Tsang, BK .
ONCOGENE, 2004, 23 (42) :6997-7004
[3]
Prognostic factors in ovarian cancer: how close are we to a complete picture? [J].
Agarwal, R ;
Kaye, SB .
ANNALS OF ONCOLOGY, 2005, 16 (01) :4-6
[4]
Two CD95 tumor classes with different sensitivities to antitumor drugs [J].
Algeciras-Schimnich, A ;
Pietras, EM ;
Barnhart, BC ;
Legembre, P ;
Vijayan, S ;
Holbeck, SL ;
Peter, ME .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (20) :11445-11450
[5]
Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[6]
Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment [J].
Bagnoli, Marina ;
Balladore, Ernanuela ;
Luison, Elena ;
Alberti, Paola ;
Raspagliesi, Francesco ;
Marcomini, Barbara ;
Canevari, Silvana ;
Mezzanzanica, Delia .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (02) :762-772
[7]
Cellular FLICE-inhibitory protein (c-FLIP) signalling: A key regulator of receptor-mediated apoptosis in physiologic context and in cancer [J].
Bagnoli, Marina ;
Canevari, Silvana ;
Mezzanzanica, Delia .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2010, 42 (02) :210-213
[8]
c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome [J].
Bagnoli, Marina ;
Ambrogi, Federico ;
Pilotti, Silvana ;
Alberti, Paola ;
Ditto, Antonino ;
Barbareschi, Mattia ;
Galligioni, Enzo ;
Biganzoli, Elia ;
Canevari, Silvana ;
Mezzanzanica, Delia .
ENDOCRINE-RELATED CANCER, 2009, 16 (02) :443-453
[9]
MicroRNAs: Target Recognition and Regulatory Functions [J].
Bartel, David P. .
CELL, 2009, 136 (02) :215-233
[10]
MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29